drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Subcutaneous CD3-directed T-cell engager bispecific antibody that binds CD3 on T cells and a B-cell tumor antigen to redirect cytotoxic T cells against malignant B cells.
nci_thesaurus_concept_id
C178408
nci_thesaurus_definition
A human bispecific antibody, with potential antineoplastic activity. Rezetamig contains two binding sites, one for the tumor-associated antigen (TAA) CD22, and one for the T-cell surface antigen CD3. Upon administration, rezetamig binds to both CD3 on T-cells and CD22-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor B-cells. CD22 is exclusively expressed on B-cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
CD3-directed bispecific antibody (rezetamig) that binds CD3 on T cells and CD22 on B-lineage tumor cells, crosslinking them to form an immune synapse, activate TCR/CD3 signaling, and induce perforin/granzyme-mediated killing of CD22+ malignant B cells, with associated cytokine release.
drug_name
JNJ-75348780
nct_id_drug_ref
NCT06139406